Cohort Descriptives

Variable Response
Cohort Name The Cognitive Health in Ageing Register: Investigational, Observational, and Trial studies in dementia research Prospective Readiness Cohort
Cohort Acronym CHARIOT: PRO Main Study
Availbility Please note that CHARIOT PRO Main cohort data is envisaged to become available via DPUK toward the end 2023.
Study Overview Identifying cognitively healthy people at high risk of developing dementia is an ever-increasing focus. The success of research in this area is dependent on having access to a well characterised, representative and sufficiently large population of individuals. The CHARIOT register is a primary care-based recruitment register for research into the prevention of dementia. The CHARIOT register was designed specifically to support recruitment into observational natural history studies of pre-symptomatic or prodromal dementia stages, and primary or secondary prevention pharmaceutical trials or other prevention strategies for dementia and other cognitive problems associated with ageing. Participants in both the Prospective Readiness Cohort (PRO) Main Study and the Substudy underwent a series of neuropsychological evaluations to characterize the patterns of cognitive change and their inter-relationship in the earliest stages of cognitive impairment. In addition, how such changes relate to the clinical presentation of cognitive impairment of the Alzheimer’s type may be evaluated over time. An opportunity is possible to identify and characterize individuals with different likelihoods of progressing along different clinical paths, which may form a framework for the evaluation of interventions.
#Subjects at Baseline 937
Institution Name Imperial College London
Department Name Neuroepidemiology and Ageing Research Unit
City London
Study/Database Website

Principal Investigator (PI) Prof Lefkos Middleton
Key Study References


Population Based Study? Yes
Family Based Study? No
Clinical based sample? No
Is there follow-up data available? No
Were participants included prior to development of dementia (may refer to controls only)? Yes
Were participants included prior to development of MCI (may refer to controls only)? Yes
How is data collected? In person: 6-monthly visits to ICL site
Who carries out data collection? Clinical staff: Research nurses, Assistant Psychologists, Clinical Psychologists
Does this take place in participants' homes or at a central location? Central location: Charing Cross Hospital, Hammersmith, London
Do participants take part individually or are families/partners involved? Individually
Dementia cases ascertained as part of study: Yes
Diagnosis based on review of existing clinical data No
Was diagnosis/primary outcomes made blind to exposure variables? No
How many times followed up? Every 6 months until 2016
# Subjects at Follow-up N/A
Study start date 2013
Study end date 2016
Is study ongoing? No
Is study still recruiting? No
Inclusion criteria Aged 60-85 inclusive. Willing and able to give written informed consent
Exclusion criteria Diagnosis of dementia of any type. Psychotic conditions


Variable type
Study ID
Age At Last Birthday
Sex Of Respondent


Sub-category Variable type Baseline Follow-up
Deprivation Socioeconomic status measures Y Y
Education Years of education Y Y
Education Level of education Y Y
Employment Employment status Y Y
Employment Occupation Y Y
Employment Income Y Y
Employment Occupation possible job matrices Y Y
Ethnicity Ethnicity Y Y

Physical Health Status

Sub-category Variable type Baseline Follow-up
Cancer Cancer Y Y
Cardiothoracic Cardiovascular Disease Y Y
Cardiothoracic Myocardial infarction Y Y
Cardiothoracic Medication use for CVD Y Y
Cardiothoracic Hypertension Y Y
Cardiothoracic Hypotension Y Y
Cardiothoracic Systolic/Diastolic BP Y Y
General Health Diabetic Status Y Y
General Health Hypercholesterolemia Y Y

Healthcare Utilisation

Sub-category Variable type Baseline Follow-up
Medications Medication use Y Y
Medications Medication for CVD Y Y

Life Functionality

Sub-category Variable type Baseline Follow-up
Daily Living Lawton IADL Y Y
Daily Living Work productivity and Activity Impairment Y Y

Psychological Status

Sub-category Variable type Baseline Follow-up
Quality Of Life Health and Lifestyle questionnaire Y Y
Quality Of Life Technology Readiness Questionnaire Y Y
Sleep Berlin questionnaire Y Y
Sleep Pittsburgh Sleep Quality Index Y Y
Sleep Actigraphy to measure sleep patterns Y Y
Wellbeing Health Utilities Index Y Y

Mental Health Status

Sub-category Variable type Baseline Follow-up
Consultation Psychiatric evaluations Y Y
Mood Geriatric Depression Scale (GDS) Y Y
Mood Speilberger State Anxiety Scale Y Y
Mood State-Trait Anxiety Scale Y Y


Sub-category Variable type Baseline Follow-up
Cognitive Performance Verbal memory Y Y
Cognitive Performance Language Y Y
Cognitive Performance Vigilence Y Y
Cognitive Performance Latent memory Y Y
Cognitive Performance IQ data Y Y
Cognitive Performance NART Y Y
Cognitive Performance MMSE Y Y
Cognitive Performance RBANS Y Y
Cognitive Performance DKEFS Y Y
Cognitive Performance Clinical Drug Research Assessment System Y Y
Cognitive Performance CogState Y Y
Cognitive Performance Neuropsychological Assessment Battery - Memory and Executive Function Y Y
Cognitive Performance ADCS-PACC Y Y
Cognitive Status Clinical Dementia Rating (CDR) Scale Y Y
Cognitive Status Revised Perceived Deficits Questionnaire Y Y
Cognitive Status Cognitive Function Index Y Y
Self Report Cognitive Status Subjective complaint Y Y


Sub-category Variable type Baseline Follow-up
Alcohol Alcohol consumption Y Y
Alcohol Specified beverage consumption Y Y
Diet Scottish Collaborative Group Food Frequency Questionnaire Y Y
Diet Diet: Carbs, protein, fats, fish Y Y
Diet Antioxidants Y Y
Diet Vegetarian Y Y
Diet Coffee and Caffeine Y Y
Diet Vitamin A, B, E Y Y
Diet Food questionnaires Y Y
Digital Technology Technology Readiness Questionnaire Y Y
Physical Type of exercise: heavy, light Y Y
Physical Exercise duration Y Y
Smoking Pack years Y Y
Smoking Current smoking Y Y
Smoking Former smoking Y Y
Smoking Passive smoking Y Y
Substances Drugs of abuse assessment Y Y

Physical Environment

Sub-category Variable type Baseline Follow-up
Housing Living situation Y Y

Physical Examination

Sub-category Variable type Baseline Follow-up
Anthropometry Height Y Y
Anthropometry Weight Y Y
Anthropometry BMI Y Y
Brain Neurological examination Y Y
Heart Blood pressure Y Y

Biosample Assays

Sub-category Variable type Baseline Follow-up
Biochemistry Abeta 1-40 Y Y
Biochemistry Abeta 1-42 Y Y
Biochemistry Urine collection Y Y
Biochemistry Saliva Y Y
Biochemistry Cortisol Y Y
Biochemistry CSF collected Y Y
Haematology Plasma Y Y
Haematology Serum Y Y


Sub-category Variable type Baseline Follow-up
MRI Structural T1 Y Y
MRI Fluid attenuation inversion recovery (FLAIR) Y Y
MRI Diffusion imaging (DTI/DWI) Y Y
MRI f-MRI (rest) Y Y
PET Amyloid Y Y
OCT Retinal imaging Y Y


Sub-category Variable type Baseline Follow-up
APOE APOE gene screening Y Y
Genotyping DNA Y Y
Genotyping RNA Y Y


Sub-category Variable type Baseline Follow-up
Blood based C-reactive protein Y Y
Blood based Estimated Glomular Filtration Rate (eGFR) Y Y
Blood based Glucose Y Y
Blood based HbA1c Y Y
Blood based Lipids Y Y
Blood based Liver function tests Y Y
Blood based Serum creatinine Y Y
Blood based Homocysteine Y Y
Blood based Floate Y Y